Bio

Ling Yang is a Managing Director at Carlyle. She is responsible for Carlyle’s healthcare investment activities in China. Ms. Yang began her career at Carlyle focusing on healthcare for the U.S. Buyout group and joined Carlyle Asia in 2011. Since joining Carlyle Asia, Ms. Yang has led investments into some of the leading healthcare companies in China including Adicon Clinical Laboratories, Ambiopharm, Microport Scientific Corporation, Meinian Onehealth, and Shenzhen Salubris Pharmaceuticals. She chairs the board of Adicon Clinical Laboratories and is a member of the board of Ambiopharm. Ms. Yang graduated summa cum laude with a B.A. in economics and computer science from Smith College and received an M.B.A. from Harvard Business School.